Background: Spending on physician-administered drugs is high and uses not approved by the US Food and Drug Administration (FDA) are frequent. Although these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence.
P hysician-administered prescription drugs are an increasingly important component of total United States drug expenditures. 1 Medicare is the dominant payer for many physician-administered drugs. 2 Recent evidence suggests 30% of these drugs use in 2010 was for clinical indications not approved by the Food and Drug Administration (FDA). 3 Thus, these drugs may be targets of future policy initiatives intending to rationalize their use.
The impact of initiatives to improve drug prescribing is dependent upon the degree to which physicians respond to emerging evidence. Prior empirical evidence has largely evaluated regulatory communications impact on oral drug utilization, [4] [5] [6] [7] [8] [9] with most studies identifying declines in drug use after safety or effectiveness concerns emerge. 4, 5, 7, 9 These studies have primarily focused on drugs prescribed in primary care settings. 4, 7, 9 Yet, physicians' responses to emerging drug safety and effectiveness evidence are likely related to the institutional setting where they are administered, 4, 6, 10, 11 as the income for some specialty physicians, such as oncologists, may be closely tied to drugs administered in outpatient offices. 2, 3, [12] [13] [14] Oncologists treating patients in private practice outpatient settings thus face direct financial incentives to closely follow the emerging evidence regarding physician-administered drugs. 1, 2, [12] [13] [14] [15] Only 1 study we are aware of examines trends in the use of a physician-administered drug after changes in evidence supporting its clinical use. 5 In that study, use of anthracyclinebased chemotherapy declined sharply and taxane-based chemotherapy increased among ambulatory breast cancer patients immediately after scientific presentations of 2 wellpublicized clinical trials in 2005.
The objective of this study is to examine trends in the use of a physician-administered chemotherapy, bevacizumab (Avastin, Genentech Inc.) for breast cancer, between its provisional FDA approval and subsequent regulatory actions ( Fig. 1) .
Bevacizumab was the first antiangiogenic drug approved by FDA for treatment of metastatic colorectal cancer (2004) and for unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer (2006). [16] [17] [18] In February 2008, the FDA granted accelerated provisional approval for bevacizumab as first-line therapy for metastatic human epidermal growth factor receptor-2 (HER-2)-negative breast cancer. [18] [19] [20] [21] The FDA's provisional approval of bevacizumab for this indication was based on early results from the Eastern Cooperative Oncology Group E2100 trial indicating an improvement in progression-free survival (PFS). 19 The FDA required Genentech to provide subsequent data to confirm the clinical benefits for PFS and overall survival. 20 Longer term follow-up of the E2100 trial, the Avastin and Docetaxel (AVADO) trial 22 and the Regimens in Bevacizumab for Breast Oncology (RIBBON-1) trial, 23 showed modest improvements in PFS but failed to demonstrate an improvement in overall survival with the addition of bevacizumab to standard chemotherapy among breast cancer patients with metastatic disease. Upon reviewing the trial data in July 2010, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted to remove the indication for breast cancer from bevacizumab's label, and in December 2010 the FDA announced its plans to withdraw approval for breast cancer. 20, 24 This announcement was followed by a June 2011 hearing where ODAC voted again to rescind bevacizumab's breast cancer indication. 20 FDA revoked bevacizumab's indication for breast cancer on November 18, 2011 ( Fig. 1 ). 25 
METHODS

Data
We used data from the Intellidose software system (AmerisourceBergen Specialty Group) for the analysis. 3, 26, 27 During the study period, Intellidose was used as the exclusive computerized method of outpatient chemotherapy order entry and billing for 122 medical oncology practices, comprising 570 oncologists across 35 states. These outpatient offices were largely physician owned or affiliated with community hospitals/clinics. The number of practices remained stable and the system did not use clinical decision aids during the study period. For each patient initiating chemotherapy, practice staff recorded date of birth, sex, cancer type, cancer stage, 28 diagnosis date, and chemotherapy date.
Sample Selection
Women with a primary diagnosis of breast cancer who were treated with bevacizumab between February 2008 and April 2012 were identified. Patients with missing cancer stage, stage 0 cancers, and those participating in a clinical trial (< 1% in each month) were excluded from analysis.
Variables
The monthly number of patients treated with bevacizumab was identified; if a patient received >2 doses in a month, it was counted only once. Each patient's cancer stage [stage IV (metastatic) vs. stages I-III (nonmetastatic)] and treatment line (first vs. second or later) were characterized. We examined patterns of bevacizumab use by outpatient office affiliation (academic, community hospital/clinic, and private), as oncologist revenues in private practice have been most closely tied to chemotherapy use. 14, 29 We also investigated use by patient age (65 y and above vs. below 65 y), because changes in use among those over 65 years of age may be related to Medicare's coverage policies. 12, 14, 29 Study Periods 
Analyses
The outcome for all analyses was the number of patients treated monthly with bevacizumab during the study period. A generalized negative binomial model was used to estimate changes in average monthly bevacizumab use compared with the pre-ODAC period, adjusting for time since approval, quarter, patient and cancer characteristics, and office affiliation. [30] [31] [32] The predicted number of patients treated monthly with bevacizumab was calculated based on model results. We present average predicted patient counts per period and percent declines per period compared with pre-ODAC meeting patient counts with 95% confidence intervals (95% CI). Tests of statistical significance in average percent declines compared with pre-ODAC levels were based on 2-sided Student t tests with unequal variances assumed derived from model estimates; P-values < 0.05 were considered statistically significant.
Sensitivity Analysis
We reestimated percent declines per period compared with pre-ODAC meeting patient counts stratified by covariates to detect policy relevant differences in bevacizumab use by patient and cancer characteristics and office affiliation, and we tested for statistical significance of interactions using 2-sided Student t tests. We reestimated models using counts of administrations (instead of patients) as the main outcome variable, as this is the typical billing unit for insurer reimbursement.
RESULTS
During the study period, most patients treated with bevacizumab had metastatic disease, received bevacizumab as second-line or later-line therapy, were younger than 65 years, and were treated in a private practice or community hospital/clinic (Table 1) .
Upon FDA approval through the quarter preceding the first ODAC meeting, there was a 54% increase in the average number of breast cancer patients who were treated with bevacizumab in a given month, from 16,280 to over 24,000 patients ( Fig. 2A) . These increases are concentrated among patients with metastatic disease ( Fig. 2A) , second-line or later-line of therapy ( Fig. 2B ), under 65 years of age (Fig. 2C) , and those treated in private practice (Fig. 2D ). Declines were observed in the number of breast cancer patients using bevacizumab coincident with the first ODAC meeting, continuing through 2012 ( Fig. 2A-D) . Table 2 reports the average predicted number of patients and estimated percent declines in patients treated with bevacizumab in each period compared with that predicted in the pre-ODAC period based on model results. In the pre-ODAC period, a monthly average of 23,682 patients used bevacizumab. From the pre-ODAC period to the period after FDA withdrawal of breast cancer approval in December 2011, there was a 65% decline (95% CI, 64%-65%) in the monthly number of patients treated with bevacizumab. The largest declines observed were during the 6-month period after the initial ODAC meeting (July 2010), during which average monthly bevacizumab use declined by 37% from the preadvisory period (95% CI, 28%-47%).
Results of the sensitivity analyses were similar to those estimated in the main models. Associations were nonsignificantly different between all patient and cancer subgroups at traditional levels (P > 0.05 for interactions of period with patient age, cancer stage, treatment line). The magnitude of the percentage decline in patients treated with bevacizumab in academic medical centers after all regulatory actions was greater than that estimated for patients treated in other settings (P-value <0.001). However, the absolute difference between these groups was small (67% decline in academic medical centers vs. 64% in community hospitals/ clinics and 65% in private practices).
DISCUSSION
This study is among the first to examine trends in prescribing of physician-administered drugs after changes in supportive evidence and subsequent regulatory actions. In a population-based audit of oncologists, bevacizumab use declined 65% after regulatory actions. The largest decline (37%) occurred after the FDA's initial evidence review in July 2010.
Although changes in bevacizumab use in response to emerging safety and effectiveness evidence could be related to changes in guideline recommendations and/or insurers' coverage policies, we did not find evidence to suggest these changes occurred. There was no change in the guideline recommendation by the National Comprehensive Care Network (NCCN), and Medicare did not alter reimbursement policy during the study period. 3, 21 Communications with the medical directors of 2 large commercial insurers [Wellpoint (34 million members) 33 and Aetna (18 million members)] 34 also reported no changes were made to their coverage of bevacizumab for breast cancer. Our findings suggest oncologists responded quickly to emerging evidence about the limited benefit to risk tradeoff of bevacizumab for breast cancer even before the FDA withdrew approval for this indication and without concomitant changes to clinical guidelines or insurers' coverage policies. Moreover, these changes likely represent a lower bound on bevacizumab use in response to regulatory actions, as the monthly patient counts included both those initiating and continuing bevacizumab treatment. Sample characteristics were consistent with other published reports regarding use of bevacizumabbased breast cancer treatment over this period, providing some additional assurance of the data's external validity. 18, 35, 36 Interestingly, after additional evidence emerged we observed slightly larger declines in use by physicians practicing in academic medical centers versus other settings, but not by other patient or cancer characteristics.
The magnitude of the decline in bevacizumab use we document is larger than that reported in primary care contexts, 4, 8, 9 but similar to declines estimated for anthracyclinebased chemotherapy for breast cancer 5 and for hormone replacement therapy use after the publication of the Women's Health Initiative. 37 The magnitude of the estimated decline might be related to the larger number of regulatory actions targeting bevacizumab. 4 Future work is needed to document whether these responses generalize to the release of new evidence in the treatment of other cancers or the use of other physician-administered drugs. Important questions remain regarding the clinical implications of the substantial declines in bevacizumab use after regulatory actions we observed. The continued recommendation of bevacizumab for breast cancer in the NCCN guidelines suggests that experts still believe bevacizumab has value in treating metastatic breast cancer despite the FDA's actions. 21 Future observational studies might leverage area-level differences in the changes in use of bevacizumab to assess whether changes in use of bevacizumab led to better outcomes for patients.
The analyses have several limitations. Although breast cancer incidence overall and by stage was stable between 2005 and 2009, the declines we estimate may be partially attributable to changes in the mix of cancer types amenable to bevacizumab treatment. In addition, although Intellidose represents a large number of practices located throughout the United States, practices using the system may be more technologically savvy and/or guideline adherent compared with average practices. 3, 13, 26 Unfortunately, we were unable to assess changes in patient or physician preferences or changes in bevacizumab promotion, nor did we have data to examine trends in prescribing variations by individual physicians or outpatient office practices. Some patients under the age of 65 may have received insurance coverage by Medicare during the study period.
In sum, bevacizumab use for breast cancer treatment declined dramatically after FDA regulatory actions in July 2010 and thereafter. Unlike previous work in primary care settings, declines in use seem to be unrelated to changes in guideline recommendations or insurance coverage. Declines in bevacizumab use suggest oncologists are responsive to emerging evidence regarding physician-administered drug safety and effectiveness.
